Pharma BD Deal Intelligence
European industry coverage emphasized that Biogen would gain full strategic, commercial, and decision-making rights, eliminating the prior collaboration…
Industry coverage of close confirmed the replacement of the prior 50/50 Biogen-Elan profit-sharing arrangement with $3.25B upfront plus tiered royalties…
Bloomberg Law characterized the close of the $3.25B Tysabri buyout as a strategic capital infusion to Elan plus a major consolidation of MS franchise economics…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Biogen Idec acquired full rights and control of Tysabri from Elan for $3.25B upfront plus tiered royalties (12%/18%/25%); originally announced Feb 6, 2013 and closed Apr 2, 2013.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) (this deal) | 2013 | $3.2B | 77 |
| Biogen Idec Inc. / Conforma Therapeutics Corporation | 2006 | $250M | 11 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
← Browse all deals · How we score deals
More: 2013 deals · Gastroenterology deals